Leading psychedelic development company focused on improving mental health MYND Life Sciences Inc. announced having received an approval to get listed on the Canadian Securities Exchange (CSE).
Shares of the company will commence trading on CSE under the ticker symbol ‘MYND’ on My 26.
The company’s chief executive officer Dr. Lyle Oberg says MYND Life Sciences will be capitalizing on this listing to expand the balance sheet of the company and also advance its clinical trials and research activities.
“We are incredibly proud to have driven MYND from incorporation, initial private financing through to securities commission approval and ultimate public listing, all in the span of just one year. Our key differentiator is built upon our proven leadership, the caliber of our Chief Science Officer and his research team, and our innovative intellectual property portfolio. We look forward to providing more information to investors over the coming weeks,” added Dr. Oberg.